Home/Stocks/BNTC

BNTC

USD

Benitec Biopharma Inc. Common Stock

$15.710+0.380 (2.479%)

Real-time Price

Healthcare

Biotechnology

United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics

Company Fundamentals

Trading Stats

Market Metrics

Open

$15.330

High

$15.770

Low

$14.550

Volume

0.13M

Company Fundamentals

Market Cap

412.4M

Industry

Biotechnology

Country

United States

Trading Stats

Avg Volume

0.05M

Exchange

NCM

Currency

USD

52-Week Range

Low $9.1Current $15.710High $17.15

Related News

Nov 4, 2025 · 05:30 PM

Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Benitec Biopharma, Raises Price Target to $35

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Benitec Biopharma with a Buy and raises the price target from $28 to $35.

Nov 4, 2025 · 12:34 PM

Analyst Upgrades

Citizens Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $22

Citizens analyst Silvan Tuerkcan maintains Benitec Biopharma with a Market Outperform and raises the price target from $20 to $22.

Nov 3, 2025 · 12:10 PM

GlobeNewswire

Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301

Fast Track Designation was granted for BB-301 following FDA review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301 BB-301 has also been granted

Nov 3, 2025 · 12:00 PM

GlobeNewswire

Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors

HAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based

Nov 3, 2025 · 12:00 AM

GlobeNewswire

Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy

HAYWARD, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines